Cas:17537-32-5 2,2,2-trideuterio-1-phenylethanol manufacturer & supplier

We serve Chemical Name:2,2,2-trideuterio-1-phenylethanol CAS:17537-32-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

2,2,2-trideuterio-1-phenylethanol

Chemical Name:2,2,2-trideuterio-1-phenylethanol
CAS.NO:17537-32-5
Synonyms:sec-Phenethyl-|A,|A,|A-d3 alcohol;1-Phenylethanol-2,2,2-d3;MFCD00084168;2,2,2-trideuterio-1-phenyl-ethanol
Molecular Formula:C8H7D3O
Molecular Weight:125.18300
HS Code:

Physical and Chemical Properties:
Melting point:19-20ºC(lit.)
Boiling point:204ºC745 mm Hg(lit.)
Density:1.048 g/mL at 25ºC
Index of Refraction:n20/D 1.532(lit.)
PSA:20.23000
Exact Mass:125.09200
LogP:1.73990

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 2937 6.1/PG 3
Packing Group:


Contact us for information like sec-Phenethyl-|A,|A,|A-d3 alcohol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,2,2-trideuterio-1-phenyl-ethanol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,2,2-trideuterio-1-phenyl-ethanol Use and application,MFCD00084168 technical grade,usp/ep/jp grade.


Related News: Inceptua has global operations with local offices across Europe, USA, and Asia 2,2,2-trideuterio-1-phenylethanol manufacturer Inceptua has global operations with local offices across Europe, USA, and Asia 2,2,2-trideuterio-1-phenylethanol supplier In addition, due to environmental constraints, Yancheng Lianhua’s first pesticide project ANBE was put into operation at a slower pace than expected, and other pesticide projects were also put into operation. 2,2,2-trideuterio-1-phenylethanol vendor This part is mainly anti-tumor drugs, prostate drugs and certain hormone drugs. 2,2,2-trideuterio-1-phenylethanol factory For Jefferies, this “has not been demonstrated to convincingly reduce Abeta plaque burden, in our view.” The firm forecasts $3 billion in global sales for gantenerumab, but at a striking 0%, “so probability so no contribution.”